Research programme: CNS and metabolic disorders therapeutics - BioFocus/Biovitrum
Alternative Names: GPCR modulators - BioFocus/Biovitrum; Serotonin 2a receptor antagonists - BioFocus/BiovitrumLatest Information Update: 15 Apr 2014
Price :
$50 *
At a glance
- Originator BioFocus DPI; Biovitrum
- Class
- Mechanism of Action G protein-coupled receptor modulators; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders; Major depressive disorder; Obesity
Most Recent Events
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 29 Jul 2005 Discontinued - Preclinical for CNS disorders in Europe (unspecified route)
- 29 Jul 2005 Discontinued - Preclinical for Depression in Europe (unspecified route)